Progression-free survival

24-month analysis: Progression-free survival demonstrated at median potential follow-up of 35.6 months1-3

Chart of progression-free survival over time Chart of progression-free survival over time

Pinch to zoom

  • In the primary analysis, the estimated 1-year PFS rate was 62% (95% CI: 45, 75), and the 2-year rate was 48% (95% CI: 29, 64)4
  • PFS and OS data were secondary endpoints of the ZUMA-2 phase 2, single-arm, open-label study and were not the primary objectives of the study5
  • PFS and OS data are not included in the USPI. PFS and OS data are descriptive and should be carefully interpreted in light of the single-arm design
  • TECARTUS is currently under accelerated approval for R/R MCL based on overall response rate and durability of response. Further clinical studies will be conducted

62% estimated 3-year OS rate (95% CI: 49, 74)1,2,6

  • Median OS was 47.6 months (95% CI: 34.9, NE) at a median potential follow-up of 35.6 months1,2,6
  • In the primary analysis, median OS was not reached, and the estimated 1-year OS rate was 83% (95% CI: 24, NE) at a median study follow-up of 12.3 months5

CI=confidence interval; MCL=mantle cell lymphoma; NE=not estimable; OS=overall survival; PFS=progression-free survival; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. Data on file [1]. Kite Pharma, Inc; 2022. 2. Data on file [2]. Kite Pharma, Inc; 2022. 3. Data on file [3]. Kite Pharma, Inc; 2022. 4. Data on file. Kite Pharma, Inc; 2020. 5. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. 6. Data on file [4]. Kite Pharma, Inc; 2022.